TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Walgreens and Boehringer Ingelheim Collaborate to Enhance Diversity in Clinical Trials

Friday, May 03, 2024

Walgreens and Boehringer Ingelheim have formed a partnership to enhance the accessibility, inclusivity, and fairness of clinical trials. They aim to enable individuals to learn about and potentially participate in a significant Phase III clinical trial at Walgreens pharmacies. This collaboration reflects their shared goal of broadening healthcare access and research opportunities.

Selected Walgreens community pharmacies will serve as clinical trial sites for individuals with obesity, overweight, and type 2 diabetes. The initiative seeks to remove barriers, improve accessibility, and ensure equitable representation in clinical trials, particularly among Black and Hispanic adults who have historically been underrepresented in medical research.

Walgreens, highlighted the joint commitment to community health and innovation. She emphasized that this model not only educates patients about clinical research but also empowers them to engage in their healthcare through trial participation. Lennart Jungersten, Senior Vice President at Boehringer Ingelheim U.S., stressed the importance of making clinical trials more accessible and inclusive, especially for populations with significant health needs.

In addition to partnering with Walgreens, Boehringer Ingelheim is collaborating with EmVenio Research to introduce mobile research units, expanding the reach and options for participation. Thad Wolfram, President of EmVenio Research, emphasized the importance of breaking down barriers and fostering inclusivity and diversity in clinical trials.

Utilizing pharmacies and mobile research units for clinical trials represents a progressive approach with the potential to improve patient outcomes and promote inclusivity. Walgreens will also leverage advanced insights to identify and engage potential study participants.

Boehringer Ingelheim's commitment to addressing cardiovascular, renal, and metabolic diseases aligns with its ambition to create innovative solutions for individuals affected by these conditions. With over a billion people worldwide living with obesity and its associated health risks, the collaboration aims to make a meaningful impact on global health.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit